Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

OCTAVE und OPERA: Missklaenge der Hypertonietherapie? [OCTAVE and OPERA: discordance in hypertension therapy?]

Item Type:Article
Title:OCTAVE und OPERA: Missklaenge der Hypertonietherapie? [OCTAVE and OPERA: discordance in hypertension therapy?]
Creators Name:Philipp, S. and Dietz, R. and Willenbrock, R.
Abstract:While ACE-inhibitors have proven their prognostic benefit in many hypertension studies, a new approach has been proposed by inhibiting neutral endopeptidase, which degrades natriuretic peptides. The combined inhibition of ACE and endopeptidase was named “vasopeptidase-inhibition” and tested in several trial. Though effective in lowering blood pressure, a superiority to ACE-inhibitors alone could not be shown. A potentially serious side effect was the increased incidence of angioneurotic edema, which led to a complete stop in the development of this pharmaceutical strategy.
Keywords:Endopeptidase, Vasopeptidase, ACE-inhibition, Bradykinin, Angioneurotic Edema
Source:Herz
ISSN:0340-9937
Publisher:Urban & Vogel
Volume:29
Number:3
Page Range:266-270
Date:1 May 2004
Official Publication:https://doi.org/10.1007/s00059-004-2537-9
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library